AVEO Oncology announces acceptance of late-breaking oral presentation of TiNivo-2 results at ESMO 2024
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
Subscribe To Our Newsletter & Stay Updated